Compare Riot Platforms Inc (RIOT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Riot Platforms Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Riot Platforms Inc trades at $16.86 (market cap $6.32B), while Vertex Pharmaceuticals Incorporated trades at $510.21 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 20.2× Riot Platforms Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Riot Platforms Inc for 16 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| RIOT | VRTX | |
|---|---|---|
Market Cap | $6.32B | $127.55B |
Volume | 30,571,756 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $28.67 | $557.96 |
52-Week Low | $11.83 | $407.37 |
Typical Hold Time | 16 Days | 120 Days |
Enterprise Value | $6.73B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RIOT stock trades at $16.69, down 9.98% with bearish technical signals despite strong analyst support. The company shows concerning fundamentals with negative net income margins (-196.28%) and ROE (-48.24%), though revenue reached $647.44M in 2025. Recent strategic shift to data center services with $9.8B in contracted lease revenue through 2048 provides long-term visibility.
While analyst consensus remains strongly bullish (94.74% buy ratings) with $31.64 price target, execution risks persist given consecutive earnings misses and negative cash flow. The AI infrastructure pivot offers growth potential but requires careful monitoring of profitability improvements and Bitcoin market volatility exposure.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
